We are live on ! Find out more
EW icon

Edwards Lifesciences

1,279 hedge funds and large institutions have $46.6B invested in Edwards Lifesciences in 2024 Q1 according to their latest regulatory filings, with 159 funds opening new positions, 436 increasing their positions, 462 reducing their positions, and 106 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more funds holding in top 10

Funds holding in top 10: 914 (+5)

50% more first-time investments, than exits

New positions opened: 159 | Existing positions closed: 106

25% more capital invested

Capital invested by funds: $37.3B → $46.6B (+$9.28B)

3% more funds holding

Funds holding: 1,2441,279 (+35)

10% more call options, than puts

Call options by funds: $431M | Put options by funds: $393M

0.75% more ownership

Funds ownership: 80.51%81.25% (+0.75%)

6% less repeat investments, than reductions

Existing positions increased: 436 | Existing positions reduced: 462

Holders
1,279
Holders Change
+35
Holders Change %
+2.81%
% of All Funds
18.42%
Holding in Top 10
14
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+55.56%
% of All Funds
0.2%
New
159
Increased
436
Reduced
462
Closed
106
Calls
$431M
Puts
$393M
Net Calls
+$38.1M
Net Calls Change
-$65.8M
Name Holding Trade Value Shares
Change
Change in
Stake
OIAM
576
OFI Invest Asset Management
France
$1.23M +$353K +4,208 +43%
RIL
577
Rothschild Investment LLC
Illinois
$1.22M +$15.4K +183 +1%
CPW
578
Cove Private Wealth
New York
$1.22M
KWA
579
Kingswood Wealth Advisors
California
$1.22M -$19.3K -230 -2%
KIC
580
Kensington Investment Counsel
California
$1.21M -$506K -6,019 -32%
OWA
581
Octavia Wealth Advisors
Ohio
$1.2M +$8.9K +106 +0.9%
AAM
582
AR Asset Management
California
$1.18M
KLWA
583
Kelly Lawrence W & Associates
California
$1.18M -$74.3K -885 -7%
CWM
584
Connecticut Wealth Management
Connecticut
$1.18M -$17.3K -206 -2%
TRCT
585
Tower Research Capital (TRC)
New York
$1.18M -$4.99M -59,411 -83%
AT
586
Arlington Trust
Alabama
$1.17M -$2.02K -24 -0.2%
BCM
587
Brookstone Capital Management
Illinois
$1.17M +$32.2K +383 +3%
GI
588
GLOBALT Investments
Georgia
$1.17M -$14K -167 -1%
PAMP
589
Polar Asset Management Partners
Ontario, Canada
$1.17M +$1.02M +12,200 New
AHB
590
Abner Herrman & Brock
New Jersey
$1.17M -$168 -2 -0%
CPBTD
591
Central Pacific Bank - Trust Division
Hawaii
$1.16M +$1.03M +12,263 New
IMC Chicago
592
IMC Chicago
Illinois
$1.15M +$1.01M +12,074 New
BFM
593
Boothbay Fund Management
New York
$1.14M +$1.01M +11,974 New
TPI
594
Trust Point Inc
Wisconsin
$1.14M +$50.3K +599 +5%
HWM
595
HB Wealth Management
Georgia
$1.14M -$4.87K -58 -0.5%
IWM
596
IHT Wealth Management
Illinois
$1.14M +$173K +2,061 +21%
WANY
597
Wealthspire Advisors (New York)
New York
$1.14M -$75.2K -895 -7%
GAM
598
Gotham Asset Management
New York
$1.13M -$543K -6,468 -35%
IWC
599
Integrated Wealth Concepts
Massachusetts
$1.13M +$12.8K +152 +1%
BL
600
Balentine LLC
Georgia
$1.12M +$583K +6,937 +144%

EW Hedge Fund Activity: Q1 2024 in Review

1,279 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q1 2024, worth a combined $46.6B — up 25% from $37.3B a quarter earlier.

Buyers outnumbered sellers: 159 funds opened new EW positions and 106 closed out — a net gain of 53 holders — while 436 added to existing stakes and 462 trimmed.

The largest buyer was Winslow Capital Management, opening a new position worth an estimated $425M. The largest seller was Capital International Investors, cutting an estimated $573M.

  • 1,279 institutional investors held Edwards Lifesciences (EW) as of Q1 2024, up from 1,244 in Q4 2023.
  • Funds reported $46.6B of Edwards Lifesciences stock for Q1 2024, up 25% quarter-over-quarter.
  • 159 funds opened new Edwards Lifesciences positions in Q1 2024 and 106 closed out, a net change of +53 holders.
  • The largest Edwards Lifesciences buyer in Q1 2024 was Winslow Capital Management, an estimated $425M added.
  • The largest Edwards Lifesciences seller in Q1 2024 was Capital International Investors, an estimated $573M sold.

Based on aggregated 13F filings for Q1 2024.